Dual-mechanism anti-CD73 antibodies CR201 and CR202 targeting distinct domains for cancer immunotherapy - Quiz - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Monoclonal Antibodies CR201 and CR202: Targeting Different Domains of CD73 for Enhanced Cancer Immunotherapy

  • By

  • Miao Zhang

  • Haibin Yuan

  • Xindi Pan

  • Xian Li

  • Zichen Wang

  • Shuping Zhang

  • Zhigang Gu

  • Biao Hu

  • Xuedong Qu

  • Qian Wang

  • Xiangguo Gu

  • Bo Wang

  • Yu Cao

  • Guilin Mu

  • Guangbo Kang

  • Ario de Marco

  • Xiangshan Zhou

  • He Huang

  • June 10, 2026

Share

Original Source(s)

Dual-mechanism anti-CD73 antibodies CR201 and CR202 targeting distinct domains for cancer immunotherapy

  • by Miao Zhang, Haibin Yuan, Xindi Pan, Xian Li, Zichen Wang, Shuping Zhang, Zhigang Gu, Biao Hu, Xuedong Qu, Qian Wang, Xiangguo Gu, Bo Wang, Yu Cao, Guilin Mu, Guangbo Kang, Ario de Marco, Xiangshan Zhou, He Huang

  • June 10, 2026

Related Content

From patient-derived tumor organoids to personalized cancer therapy: advancing treatment for advanced solid tumors

Rapid metastatic progression of primary pulmonary synovial sarcoma despite guideline-concordant multimodal therapy: a case report

Commentary: Case Report: Giant atypical granular cell tumor of the median nerve